PL2427485T3 - Epitopy CD133 - Google Patents

Epitopy CD133

Info

Publication number
PL2427485T3
PL2427485T3 PL10772898T PL10772898T PL2427485T3 PL 2427485 T3 PL2427485 T3 PL 2427485T3 PL 10772898 T PL10772898 T PL 10772898T PL 10772898 T PL10772898 T PL 10772898T PL 2427485 T3 PL2427485 T3 PL 2427485T3
Authority
PL
Poland
Prior art keywords
epitopes
Prior art date
Application number
PL10772898T
Other languages
English (en)
Inventor
Manish Singh
James Bender
Original Assignee
Immunocellular Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocellular Therapeutics Ltd filed Critical Immunocellular Therapeutics Ltd
Publication of PL2427485T3 publication Critical patent/PL2427485T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1274Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL10772898T 2009-05-07 2010-05-07 Epitopy CD133 PL2427485T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17630209P 2009-05-07 2009-05-07
EP10772898.2A EP2427485B1 (en) 2009-05-07 2010-05-07 Cd133 epitopes
PCT/US2010/034082 WO2010129895A2 (en) 2009-05-07 2010-05-07 Cd133 epitopes

Publications (1)

Publication Number Publication Date
PL2427485T3 true PL2427485T3 (pl) 2017-10-31

Family

ID=43050907

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10772898T PL2427485T3 (pl) 2009-05-07 2010-05-07 Epitopy CD133

Country Status (7)

Country Link
US (2) US8383768B2 (pl)
EP (1) EP2427485B1 (pl)
DK (1) DK2427485T3 (pl)
ES (1) ES2618573T3 (pl)
PL (1) PL2427485T3 (pl)
PT (1) PT2427485T (pl)
WO (1) WO2010129895A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037995A2 (en) * 2003-10-06 2005-04-28 Cedars-Sinai Medical Center Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy
EP2084267B1 (en) 2006-09-26 2018-04-11 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US8871211B2 (en) * 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US9068020B2 (en) * 2008-09-02 2015-06-30 Cedars-Sinai Medical Center CD133 epitopes
PL2427485T3 (pl) 2009-05-07 2017-10-31 Immunocellular Therapeutics Ltd Epitopy CD133
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
ES2662333T3 (es) 2013-02-14 2018-04-06 Immunocellular Therapeutics Ltd. Vacunas contra el cáncer y métodos de vacunación
US20150359867A1 (en) * 2013-02-14 2015-12-17 Immunocellular Therapeutics, Ltd. Ovarian cancer vaccines and vaccination methods
AU2015205756A1 (en) 2014-01-10 2016-07-21 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating EGFR expressing tumors
EP4001311A1 (en) 2014-07-09 2022-05-25 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
KR101726212B1 (ko) * 2015-05-08 2017-04-13 한양대학교 산학협력단 Cd133 검출용 다중 펩타이드 프로브
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-cd20组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-egfr组合
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
AU2017419352B2 (en) 2017-06-23 2024-05-30 Birdie Biopharmaceuticals, Inc. Pharmaceutical compositions

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク,インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
DE69333433T2 (de) 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5550214A (en) 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
CA2207736A1 (en) 1994-12-14 1996-06-20 The Scripps Research Institute In vivo activation of tumor-specific cytotoxic t cells
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US6010905A (en) 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US5843633A (en) 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
US6455678B1 (en) 1996-04-26 2002-09-24 Amcell Corporation Human hematopoietic stem and progenitor cell antigen
US6458585B1 (en) 1996-08-14 2002-10-01 Nexell Therapeutics Inc. Cytokine-free culture of dendritic cells
US7368531B2 (en) * 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
WO1999031117A1 (en) * 1997-12-18 1999-06-24 Human Genome Sciences, Inc. 110 human secreted proteins
WO1998053048A1 (en) 1997-05-21 1998-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells
US20020034819A1 (en) 1998-02-23 2002-03-21 Alan K. Smith Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both; methods for obtaining same; and their uses
US7186409B2 (en) 1998-08-14 2007-03-06 The Children's Medical Center Corporation Neural stem cells and use thereof for brain tumor therapy
US20020115213A1 (en) 1998-08-14 2002-08-22 Northeastern Ohio Universities Of Medicine Engraftable neural progenitor & stem cells for brain tumor therapy
AU6144499A (en) 1998-09-15 2000-04-03 University Of Pittsburgh In situ injection of antigen-presenting cells with genetically enhanced cytokineexpression
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
WO2000024778A1 (en) 1998-10-26 2000-05-04 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Hla-a2 and hla-dr specific peptide epitopes from the melanoma antigen trp2
GB9824306D0 (en) 1998-11-05 1998-12-30 Isis Innovation Method for producing dendritic dells
KR20010109275A (ko) 1998-12-23 2001-12-08 로저 에이. 윌리암스 종양치료의 병용치료로서 사이클로옥시게나제-2 억제제와기질 금속단백분해효소 억제제를 사용하는 방법
CA2359892A1 (en) * 1999-01-08 2000-07-13 Panacos Pharmaceuticals, Inc. Methods of eliciting broadly neutralizing antibodies targeting hiv-1 gp41
DE60035191T2 (de) 1999-05-03 2008-06-19 Neuro Therapeutics Ab Materialien und methoden zur entwicklung von dopaminergen neuronen
US6566395B1 (en) 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
US20030204052A1 (en) * 2000-10-04 2003-10-30 Herrmann John L. Novel proteins and nucleic acids encoding same and antibodies directed against these proteins
US20070098776A1 (en) 1999-12-13 2007-05-03 Fikes John D HLA class I A2 tumor associated antigen peptides and vaccine compositions
AU2273701A (en) 1999-12-13 2001-06-18 Epimmune, Inc. Hla class i a2 tumor associated antigen peptides and vaccine compositions
US20060003323A1 (en) * 2000-03-01 2006-01-05 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU4744201A (en) 2000-03-15 2001-09-24 Childrens Medical Center Systemic gene delivery vehicles for the treatment of tumors
US20020076707A1 (en) 2000-06-30 2002-06-20 David Mack Novel methods of diagnosing cancer, compositions, and methods of screening for cancer modulators
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
DK1326961T3 (da) 2000-09-15 2008-01-07 Ortho Mcneil Pharm Inc Sammensætninger og fremgangsmåder tl inducering af specifikke cytolytiske T-cellereaktioner
US20030202963A1 (en) 2000-10-12 2003-10-30 Cornell Research Foundation, Inc. Method of treating cancer
US6632459B2 (en) 2000-12-11 2003-10-14 Nutricia N.V. Chlorogenic acid and an analog thereof for immune system stimulation
CN1168740C (zh) 2001-04-04 2004-09-29 上海美恩生物技术有限公司 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
DE10132502A1 (de) 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
US20040241147A1 (en) 2001-07-25 2004-12-02 Alessandra Nardin New isolated dendritic cells, a process for preparing the same and their use in pharmaceutical compositions
GB0119346D0 (en) 2001-08-08 2001-10-03 Bioclones Proprietary Ltd Process for the maturation of dendritic cells
US7763243B2 (en) 2001-08-17 2010-07-27 Roger Williams Medical Center In situ immunization
PL372098A1 (pl) 2001-09-06 2005-07-11 Northwest Biotherapeutics, Inc. Kompozycje i sposoby dla aktywacji monocytowych komórek dendrytycznych oraz komórek T w kierunku odpowiedzi TH-1
US20040072246A1 (en) 2001-09-11 2004-04-15 Roland Martin System and method for identifying t cell and other epitopes and the like
JP2005510491A (ja) 2001-10-26 2005-04-21 イミュノ−アールエックス, インコーポレイテッド 免疫抑制を逆転させるための免疫治療
CA2474778A1 (en) 2002-02-08 2003-08-14 Peter Carmeliet A novel target to inhibit angiogenesis
US7413869B2 (en) 2002-04-05 2008-08-19 Dendreon Corporation Method for determining potency of antigenic presenting cell based vaccines
WO2003102155A2 (en) * 2002-06-03 2003-12-11 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7204982B2 (en) 2002-07-02 2007-04-17 The Regents Of The University Of California Compositions and methods for treatment and detection of multiple cancers
US20040057935A1 (en) 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
US20040197903A1 (en) 2003-01-31 2004-10-07 Northwest Biotherapeutics, Inc. Method for induction of proliferation of natural killer cells by dendritic cells cultured with GM-CSF and IL-15
KR101201875B1 (ko) 2003-02-27 2012-11-15 노쓰웨스트 바이오써라퓨틱스, 인크. 부가의 사이토킨의 부재하에 gm-csf를 사용한 단핵구수지상 전구체 세포로부터의 수지상 세포 생성방법
WO2005037995A2 (en) 2003-10-06 2005-04-28 Cedars-Sinai Medical Center Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy
JP5015601B2 (ja) 2003-10-21 2012-08-29 セダーズ−シナイ メディカル センター 中枢神経系の癌を含む癌の処置のための系および方法
WO2005079581A1 (en) 2004-01-20 2005-09-01 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
US20060204509A1 (en) 2005-03-14 2006-09-14 Harty John T Accelerated CD8+ T-cell memory after dendritic cell vaccination
US20100040637A1 (en) 2005-11-23 2010-02-18 Karen Van Orden Methods and Composition for Treating Diseases Targeting Prominin-1 (CD133)
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP2084267B1 (en) 2006-09-26 2018-04-11 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US8871211B2 (en) 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
CN102016582A (zh) 2006-10-31 2011-04-13 国家干细胞控股公司 鉴别、分离和利用来自成人胰腺的内分泌祖细胞的方法
ITMI20062100A1 (it) 2006-10-31 2008-05-01 Fondazione I R C C S Istituto Neurologico Metodo per la stimolazi0ne di cellule dendritiche e prodotto cellulare cosi'ottenuto per la immunoterapia autologa di tumori solidi umani
EP1958649A1 (en) 2007-02-14 2008-08-20 Graftys Injectable calcium-phosphate cement releasing a bone resorption inhibitor
US9068020B2 (en) 2008-09-02 2015-06-30 Cedars-Sinai Medical Center CD133 epitopes
PL2427485T3 (pl) 2009-05-07 2017-10-31 Immunocellular Therapeutics Ltd Epitopy CD133

Also Published As

Publication number Publication date
US8604167B2 (en) 2013-12-10
EP2427485A2 (en) 2012-03-14
US8383768B2 (en) 2013-02-26
PT2427485T (pt) 2017-03-13
ES2618573T3 (es) 2017-06-21
WO2010129895A2 (en) 2010-11-11
DK2427485T3 (en) 2017-03-13
WO2010129895A3 (en) 2011-04-28
US20100310643A1 (en) 2010-12-09
US20130115279A1 (en) 2013-05-09
EP2427485A4 (en) 2013-07-10
EP2427485B1 (en) 2016-12-07

Similar Documents

Publication Publication Date Title
PL2427485T3 (pl) Epitopy CD133
GB2489902B (en) Interface
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
ZA201104545B (en) Anti-siglec-15 antibody
GB0909906D0 (en) Antibodies
GB201115621D0 (en) Interface
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
GB0918375D0 (en) Construct
EP2499707A4 (en) INTERFACE
PL2328923T3 (pl) Epitopy CD133
GB0920324D0 (en) Antibodies
EP2508411A4 (en) STRUCTURE
HK1170745A1 (en) Antibodies against il-17br il-17br
GB0922659D0 (en) Factor H
GB2473934B (en) Anti-VEEV antibody
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
EP2424892A4 (en) DC-STAMP ANTIBODY
GB0909743D0 (en) Antifungal targgt
TWM387524U (en) Rod clamper
GB0903969D0 (en) Selection interface
GB0908945D0 (en) Antibodies
GB0911712D0 (en) Antibody
ZA201008616B (en) Structure
TWM373647U (en) Insect-trapping structure